These findings highlight the therapeutic potential of Baricitinib in APOL1-associated kidney diseases, as applied in the Phase 2 clinical JUSTICE trial, which evaluated its efficacy in reducing proteinuria in individuals carrying high-risk APOL1 genotypes [60]. Here, APOL1 is linked to kidney disorder.